USPTO Art Unit 1699 Prosecution Statistics

Art Unit Information

Art Unit: 1699
Group: 1690
Tech Center: 1600
Total Cases: 4,109
Last Active: September 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19320020CHEMICAL COMPOUNDS AND USES THEREOFSeptember 2025February 2026Allow510NoNo
19256777OCEANOBACILLUS JEDDAHENSE STRAIN HMF12 AND ITS APPLICATIONJuly 2025December 2025Allow610YesNo
19250795COMPOSITIONJune 2025February 2026Allow810YesNo
19247553GPX4 Inhibitors and Senolytic Compounds and Uses ThereofJune 2025July 2025Allow100NoNo
19230710Animal Feeds and Feed Premixes Containing Betaine and a PhytaseJune 2025November 2025Allow510NoNo
19223085METHOD FOR SEPARATING AMOXICILLIN AND PHENYLACETIC ACID FROM REACTION SOLUTION IN ONE-STEP ENZYMATIC SYNTHESIS OF AMOXICILLINMay 2025July 2025Allow200YesNo
19217261Biopreparation Against Ectoparasites of Cattle and Method of Application ThereofMay 2025September 2025Allow410YesNo
19189316ONE-STEP METHOD FOR SYNTHESIZING AMOXICILLIN FROM PENICILLIN OR SALT THEREOF THROUGH ENZYME CATALYSISApril 2025September 2025Allow511NoNo
19180258APPARATUS AND METHODS USING TETHERED ENZYMES FOR THE DETECTION OF THE ENZYMATIC ACTIVITY OF BIOMARKERSApril 2025December 2025Abandon811NoNo
19075754TOPRAMEZONE DERIVATIVE AND USE THEREOFMarch 2025December 2025Allow910NoNo
19048619USE OF PLATELET-BASED PRODUCTS FOR TREATMENT OF CAPSULAR CONTRACTURE PROXIMATE BREAST IMPLANTFebruary 2025September 2025Allow700YesNo
19046435COMPOSITIONS AND METHODS FOR MINIMUM RISK PEST CONTROLFebruary 2025April 2025Allow200YesNo
19030861TREATMENT OF IMMUNE DISORDERSJanuary 2025January 2026Allow1210NoNo
19022162PROTEOLYTIC ENZYME COMPOSITIONJanuary 2025September 2025Allow820NoNo
19021046PREPARATION METHOD FOR POWDER PRODUCT, POWDER PRODUCT, AND POWDER COMMODITYJanuary 2025June 2025Allow501NoNo
19017364ANTI-MICROBIAL TREATMENT FOR SEEDS AND CROPSJanuary 2025April 2025Allow300YesNo
18870764COSMETIC COMPOSITIONDecember 2024April 2025Allow400NoNo
18957012COMPOUND COMPRISING SELF-IMMOLATIVE GROUP AND LIGAND-DRUG CONJUGATE COMPRISING SAMENovember 2024October 2025Allow1121NoNo
18955005ADDITIVE INGREDIENTS OF SYNERGISTS AND SURFACTANTS PROVIDED IN A SINGLE-USE TRANSPORTER PREFERABLY FOR USE WITH WEED CONTROL, INSECT CONTROL AND MOLD REMOVAL COMPOSITIONSNovember 2024November 2025Allow1120YesNo
18951938BIOCATALYSTS FOR ORGANIC SYNTHESISNovember 2024January 2026Allow1421NoNo
18848797METHOD FOR PRODUCING NUCLEIC ACID OLIGOMERSeptember 2024August 2025Allow1110NoNo
18844103COMPOUND IN WHICH POLYGLYCEROL, FATTY ACID, AND DICARBOXYLIC ACID HAVE BEEN ESTERIFIEDSeptember 2024August 2025Allow1111NoNo
18822733NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOFSeptember 2024December 2025Allow1520NoNo
18842208ENCAPSULATED COMPOSITIONSAugust 2024October 2025Allow1321NoNo
18809625PSMA Imaging AgentsAugust 2024December 2025Allow1620YesNo
18807866NANOPARTICLES COMPRISING A FUNCTIONAL AGENT AND METHOD OF PREPARATION AND USE THEREOFAugust 2024May 2025Allow921YesNo
18832730AZIDE-FUNCTIONALIZED COPOLYMERSJuly 2024July 2025Allow1211YesNo
18783039NANO PESTICIDAL FORMULATION AND PREPARATION METHOD THEREOFJuly 2024March 2025Allow820NoNo
18775693POLYSILANE METHACRYLIC COMPOUNDS AND METHODS OF MAKING THEMJuly 2024September 2024Allow200NoNo
18775678POLYSILANE METHACRYLIC COMPOUNDS AND METHODS OF MAKING THEMJuly 2024September 2024Allow200NoNo
18769974INSECT, BACTERIAL, AND/OR FUNGAL CONTROL COMPOSITIONJuly 2024October 2025Abandon1510YesNo
18763218METHODS FOR QUANTIFYING STARCH AND CELLULOSE IN CORN SAMPLESJuly 2024November 2025Allow1611YesNo
18760458DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOFJuly 2024June 2025Allow1110NoNo
18675867Natural Oil Composition for Improving Hair GrowthMay 2024March 2026Allow2200YesNo
18665923FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITYMay 2024June 2025Allow1311YesNo
18662947INHIBITORS OF BUNYAVIRIDAE AND USES THEREOFMay 2024March 2025Allow1010YesNo
18662301Preparation method and application of water-soluble chlorhexidine hyaluronate antibacterial agentsMay 2024December 2024Allow720YesNo
18659052SUBSTITUTED NITROGEN CONTAINING COMPOUNDSMay 2024June 2025Abandon1310NoNo
18657963THERAPEUTIC COMPOUNDS AND METHODSMay 2024July 2025Allow1420NoNo
18653104Agricultural compositions and methods for the delivery of plant health-promoting microbesMay 2024March 2026Allow2231YesNo
18653713PHARMACEUTICAL COMPOSITIONMay 2024July 2025Allow1431YesNo
18640607THERAPEUTICALLY ACTIVE STEROIDAL DERIVATIVESApril 2024May 2025Abandon1310NoNo
18634556POLYSILANE METHACRYLIC COMPOUNDS AND METHODS OF MAKING THEMApril 2024July 2024Allow401NoNo
18631626POPULATION GENETICS APPROACH TO BIOLOGICAL CONTROL OF MYCOTOXIN PRODUCTIONApril 2024August 2025Allow1611NoNo
18625676Animal Feeds and Feed Premixes Containing Betaine Hydrochloride and a PhytaseApril 2024April 2025Allow1210NoNo
18625655CATIONIC POLYMERSApril 2024March 2025Allow1200NoNo
18618511ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORSMarch 2024September 2025Allow1711NoNo
18696209Weed Seed Germination InhibitorMarch 2024July 2025Allow1621YesNo
18606927CLINICAL FORMULATIONSMarch 2024May 2025Allow1420NoNo
18600631ADDITIVE INGREDIENTS OF SYNERGISTS AND SURFACTANTS PROVIDED IN A SINGLE-USE TRANSPORTER PREFERABLY FOR USE WITH WEED CONTROL, INSECT CONTROL AND MOLD REMOVAL COMPOSITIONSMarch 2024August 2024Allow501YesNo
18596521METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTIONMarch 2024December 2025Allow2121NoNo
18589142Methods and Compositions Relating to Microbial Treatment and Diagnosis of DisordersFebruary 2024September 2025Allow1920NoNo
18587753NOVEL SMALL MOLECULE COMPOUNDFebruary 2024April 2025Allow1310NoNo
18587730CARDIAC SARCOMERE INHIBITORSFebruary 2024October 2024Allow700NoNo
18584709METHOD OF DETECTING SALMONELLA TYPHIMURIUMFebruary 2024March 2025Allow1210YesNo
18685079ORAL FILM UNIT DOSAGE FORMFebruary 2024January 2026Allow2300NoNo
18435744COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITYFebruary 2024April 2025Abandon1501NoNo
18681524METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF CANCER OF THE BILIARY TRACTFebruary 2024November 2024Allow911YesNo
18433950ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17February 2024February 2025Allow1310NoNo
18433029Methods and Compositions for Determining pHFebruary 2024June 2025Abandon1611NoNo
18429524METHODS OF TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERSFebruary 2024February 2025Abandon1301NoNo
18424597CELL POPULATIONS OF CD31-POSITIVE, CD45-NEGATIVE, CD200-POSITIVE MAMMALIAN CELLS AND USE THEREOFJanuary 2024February 2025Allow1200NoNo
18417535SUSTAINABLE NANOPARTICLE FORMULATION FOR MANAGEMENT OF RED PALM WEEVILJanuary 2024April 2024Allow300YesNo
18413175PROCESSES FOR PREPARING AG-10, ITS INTERMEDIATES, AND SALTS THEREOFJanuary 2024August 2024Allow700NoNo
18412907SE33 MUTATIONS IMPACTING GENOTYPE CONCORDANCEJanuary 2024March 2025Abandon1410NoNo
18410273EFFICIENT LIPID DELIVERY TO HUMAN TEAR FILM USING A SALT-SENSITIVE EMULSION SYSTEMJanuary 2024July 2025Abandon1810NoNo
18409042CARRIER-FREE CURCUMIN NANOPARTICLES FOR EGFR-POSITIVE CANCER THERAPYJanuary 2024June 2025Allow1701NoNo
18404478N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODSJanuary 2024April 2025Allow1620YesNo
18403151EYE DROP FORMULATION WITH ENHANCED PROPERTIES BY COMBINING SODIUM HYALURONATE WITH CARBOXYMETHYLCELLULOSEJanuary 2024October 2025Abandon2110NoNo
18390083APPARATUS AND METHODS USING TETHERED ENZYMES FOR THE DETECTION OF THE ENZYMATIC ACTIVITY OF BIOMARKERSDecember 2023March 2025Allow1521YesNo
18545335CELL CULTURE MEDIA COMPOSITIONS FOR PRIMARY CELLSDecember 2023March 2025Allow1511NoNo
18538176Boronated Multifunctional Targeting Drug Conjugates, Their Uses and Methods for Their PreparationDecember 2023March 2025Abandon1501NoNo
18524351MICROBIAL COMPOSITIONS AND METHODS FOR RUMINANT HEALTH AND PERFORMANCENovember 2023October 2025Abandon2211NoNo
18524807AZABICYCLO AND DIAZEPINE DERIVATIVESNovember 2023October 2024Allow1110NoNo
18522676LUBRICANT FORMULATIONSNovember 2023December 2025Allow2501NoNo
18521400HETEROARYL CARBOXAMIDE COMPOUNDNovember 2023April 2024Allow511NoNo
18516940GRANULE FOR DETECTING GLUCOSE IN PET URINE AND METHOD FOR PREPARING THE SAMENovember 2023May 2024Allow610NoNo
18510936AMINATED PSILOCYBIN DERIVATIVES AND METHODS OF USINGNovember 2023March 2025Allow1631YesNo
18508838COMPOSITION FOR AMELIORATING OR TREATING DEMENTIA CONTAINING 2'-FUCOSYLLACTOSENovember 2023January 2025Allow1420NoNo
18507595DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND USES THEREOFNovember 2023April 2024Allow510YesNo
18507409METHOD FOR SELECTIVE RECOVERY OF LIPOPHILIC COMPOUNDSNovember 2023October 2024Abandon1110NoNo
18506179POLYPEPTIDES HAVING LYZOZYME ACTIVITY, POLUNUCLEOTIDES ENCODING SAME AND USES AND COMPOSITIONS THEREOFNovember 2023June 2025Allow1911NoNo
18388728{5-CHLORO-2-(2-(3-(SUBSTITUTEDPHENYL)-1,2,4-OXADIAZOL-5-YL)ETHYL)PHENYL}(PHENYL)METHANONES AS LARVICIDAL AGENTSNovember 2023March 2024Allow410NoNo
18505713CRYSTALLINE IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONSNovember 2023January 2025Allow1410YesNo
183865613-(4-NITROPHENYL)-5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow300NoNo
18500708ETHYLENE OXIDE ABSORPTION LAYER FOR ANALYTE SENSING AND METHODNovember 2023July 2025Allow2020NoNo
18385345Fragrant Horticultural Care CompositionOctober 2023December 2024Allow1310YesNo
18493935GENES AND GENE SIGNATURES FOR DIAGNOSIS AND TREATMENT OF MELANOMAOctober 2023March 2025Allow1710YesNo
18494167Methods and Compositions for Improving Quality of Life and Increasing Activity in Aging and Chronically Ill MammalsOctober 2023October 2025Allow2420YesNo
183828191-(2-CHLOROBENZYLIDENEAMINO)-5,5-DIPHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow310NoNo
183829724,5-BIS(4-CHLOROPHENYL)-2-PHENYL-1H-IMIDAZOL-1-YL AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow510NoNo
18491523HETEROCYCLIC COMPOUNDS AS PESTICIDESOctober 2023April 2025Abandon1801NoNo
18555405ANHYDROUS COMPOSITION FOR CARING FOR AND/OR MAKING UP KERATIN MATERIALSOctober 2023October 2025Allow2400NoNo
18485699BIARYL AMIDES WITH MODIFIED SUGAR GROUPS FOR TREATMENT OF DISEASES ASSOCIATED WITH HEAT SHOCK PROTEIN PATHWAYOctober 2023October 2025Allow2511YesNo
18286725EMBOLIZATION HYDROGEL HAVING CONTROLLABLE DEGRADATION TIME, AND PREPARATION METHOD THEREFOROctober 2023March 2026Allow2911NoNo
18484734N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-4-METHOXYBENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023December 2023Allow200YesNo
18554695HAIR TREATMENT METHODOctober 2023October 2025Allow2400NoNo
18484397N-[(2-{[(FURAN-YLCARBONYL)CARBAMOTHIOYL]AMINO}PHENYL)CARBAMOTHIOYL]FURAN-2-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)October 2023March 2024Allow510YesNo
18480790ENZYME MEDIATOR FUNCTIONALIZED POLYMERS FOR USE WITH ANALYTE SENSORSOctober 2023September 2025Allow2401YesNo
18477766MICROBIAL COMPOSITIONS FOR FOWL HEALTH AND PERFORMANCESeptember 2023July 2025Abandon2210NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1699.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
54
Examiner Affirmed
39
(72.2%)
Examiner Reversed
15
(27.8%)
Reversal Percentile
25.6%
Lower than average

What This Means

With a 27.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
274
Allowed After Appeal Filing
79
(28.8%)
Not Allowed After Appeal Filing
195
(71.2%)
Filing Benefit Percentile
29.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 28.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1699 - Prosecution Statistics Summary

Executive Summary

Art Unit 1699 is part of Group 1690 in Technology Center 1600. This art unit has examined 4,109 patent applications in our dataset, with an overall allowance rate of 75.3%. Applications typically reach final disposition in approximately 32 months.

Comparative Analysis

Art Unit 1699's allowance rate of 75.3% places it in the 45% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1699 receive an average of 1.98 office actions before reaching final disposition (in the 57% percentile). The median prosecution time is 32 months (in the 40% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.